8-K: Sensus Healthcare Reports Strong Q3 2024 Results with Revenue More Than Doubling

Sensus Healthcare's third quarter 2024 financial results show a significant increase in revenue, more than doubling compared to the same period last year, and a return to profitability.

Summary

• Sensus Healthcare announced its financial results for the third quarter of 2024, showing substantial growth.
• Revenues for the quarter reached $8.8 million, a 127% increase compared to $3.9 million in the third quarter of 2023.
• The company shipped 27 systems in Q3 2024, including one international sale, compared to 11 systems in the same quarter of the previous year.
• Net income for the quarter was $1.2 million, or $0.07 per diluted share, a significant improvement from a net loss of $1.5 million, or $0.09 per share, in Q3 2023.
• Adjusted EBITDA was $1.6 million, compared to a negative $1.7 million in the prior year's quarter.
• The company ended the quarter with $22.6 million in cash and cash equivalents and no debt.
• For the nine months ended September 30, 2024, revenues were $28.7 million, a 143% increase compared to $11.8 million in the same period of 2023.
• Net income for the nine-month period was $5.1 million, or $0.31 per diluted share, compared to a net loss of $3.7 million, or $0.23 per share, in the prior year.
• Adjusted EBITDA for the nine-month period was $6.7 million, compared to a negative $5.4 million in the same period of 2023.
• The company has signed 22 Fair Deal Agreements for its SRT-100 Vision (IG-SRT) units since the program's launch in March, exceeding their goal of 50 agreements by the end of 2024.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to the significant revenue growth, return to profitability, and successful implementation of the Fair Deal Agreement model. The company's strong cash position and positive future outlook further contribute to the high sentiment score.

Positives

• The company's revenue more than doubled year-over-year for the second consecutive quarter.
• Sensus Healthcare achieved profitability despite the summer seasonality of its business.
• The Fair Deal Agreement model is attracting significant attention and is expected to contribute to future growth.
• The company has exceeded its goal of having up to 50 Fair Deal Agreements signed by the end of 2024.
• The company's proprietary HIPAA-compliant software, Sentinel IT, is considered a valuable asset.
• The company has a strong cash position with $22.6 million and no debt.
• Gross profit margin improved to 59.3% in Q3 2024 from 51.0% in Q3 2023.
• The company has seen a decrease in selling and marketing expenses for the nine months ended September 30, 2024, compared to the same period in 2023.
• Research and development expenses have decreased for both the three and nine month periods ended September 30, 2024, compared to the same periods in 2023.

Negatives

• Accounts receivable increased to $17.0 million as of September 30, 2024, compared to $10.6 million as of December 31, 2023, due to increased sales and extended payment terms with a large customer.
• General and administrative expenses increased due to higher compensation and bad debt expense.
• Cost of sales increased due to a higher number of units sold.

Risks

• The company's ability to maintain profitability is a risk factor.
• The company's ability to sell the anticipated number of SRT units for the remainder of 2024 is a risk.
• Inflationary pressures could impact sales.
• Changes in government or third-party payor reimbursement for procedures using their products could affect sales.
• Regulatory requirements and competition pose risks.
• The company faces risks from doing business in China and other foreign countries.
• Concentration of customers in the U.S. and China, including a large customer, is a risk.
• The company's information technology systems and data security are potential risks.
• The company's ability to protect its intellectual property is a risk.
• The company is subject to risks related to the Middle East conflict, the Russian invasion of Ukraine and global geopolitical uncertainties.

Future Outlook

The company expects to generate recurring revenue from the Fair Deal Agreements in 2025 and anticipates continued growth due to the increasing utilization of SRT for non-melanoma skin cancer and keloid scars.

Management Comments

• Joe Sardano, chairman and chief executive officer, stated that continued growth in revenues and earnings reflects the company's success in engaging customers with both existing and new sales options.
• Joe Sardano noted that the company's revenues more than doubled year-over-year for the second consecutive quarter and that they maintained profitability despite the summer seasonality of their business.
• Joe Sardano highlighted that the revenue-sharing Fair Deal Agreement continues to attract significant attention.
• Joe Sardano mentioned that the signing of an agreement with Platinum Dermatology Partners is a major step forward.
• Anthony Petelin, M.D., president of Platinum Dermatology Partners, expressed excitement about the expanded services agreement with Sensus Healthcare.
• Joe Sardano stated that the company has exceeded its goal of having up to 50 Fair Deal Agreements signed by the end of 2024.
• Joe Sardano believes that the market for non-melanoma skin cancer treatments is enormous and that SRT is becoming the people's choice for treatment.

Industry Context

The announcement highlights the growing adoption of superficial radiotherapy (SRT) for treating non-melanoma skin cancer, aligning with the increasing interest in non-invasive and minimally invasive treatment options within the dermatology and radiation oncology fields. The Fair Deal Agreement model is a novel approach that could disrupt traditional sales models in the medical device industry.

Comparison to Industry Standards

• Sensus Healthcare's revenue growth of 127% in Q3 2024 significantly outperforms many established medical device companies, which typically see single-digit or low double-digit growth rates.
• The company's shift to profitability, with a net income of $1.2 million in Q3 2024, is a notable achievement compared to companies still in the growth phase that often report losses.
• The Fair Deal Agreement model is a unique approach, unlike traditional sales models used by competitors such as Accuray or Varian Medical Systems, which focus on direct sales of equipment.
• The company's focus on non-invasive treatments for skin cancer positions it well in a market where patients are increasingly seeking less invasive alternatives to traditional surgery or chemotherapy.
• The company's gross profit margin of 59.3% in Q3 2024 is competitive with other medical device companies, indicating efficient cost management.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and positive future outlook.
• Employees may benefit from the company's growth and success.
• Customers, including healthcare providers and patients, will have increased access to the company's SRT technology.
• Suppliers may see increased demand for their products and services.
• Creditors will likely view the company's financial health favorably.

Next Steps

• The company expects to generate recurring revenue from the Fair Deal Agreements in 2025.
• The company will continue to monitor the market for non-melanoma skin cancer treatments.
• The company will continue to develop and market its SRT technology.

Key Dates

Keywords

Sensus Healthcare, SRT, Superficial Radiotherapy, IG-SRT, Fair Deal Agreement, Non-Melanoma Skin Cancer, Medical Devices, Revenue, EBITDA, Net Income, Healthcare, Oncology